Cepharanthine
Synonyms: CEP
Tags:
drug
small molecule
PubChem: 10206 10206 Related interactions
Related publications
Title
Author
Type
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG
Research
Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi, Koichi Watashi, Wakana Saso, Kaho Shionoya, Shoya Iwanami, Takatsugu Hirokawa, Tsuyoshi Shirai, Shigehiko Kanaya, Yusuke Ito, Kwang Su Kim, Kazane Nishioka, Shuji Ando, Keisuke Ejima,
Research
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Jeon, Sangeun and Ko, Meehyun and Lee, Jihye and Choi, Inhee and Byun, Soo Young and Park, Soonju and Shum, David and Kim, Seungtaek
Research
Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S 2 and MERS-S pseudotyped particles Catherine Z. Chen, Miao Xu, Manisha Pradhan , Kirill Gorshkov, Jennifer Petersen, Marco R. Straus, Wei Zhu, Paul Shinn, Hui Guo, Min Shen, Carleen Klumpp-Thomas, Samuel G. Michael, Joshua Zimmerberg, Wei Zheng, Gary R. Whittaker
Research
Prioritization of potential drugs targeting the SARS-CoV-2 main protease Yanjin Li, Yu Zhang, Yikai Han, Tengfei Zhang, Ranran Du
Research
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro Nir Drayman, Krysten A. Jones, Saara-Anne Azizi, Heather M. Froggatt, Kemin Tan, Natalia Ivanovna Maltseva, Siquan Chen, Vlad Nicolaescu, Steve Dvorkin, Kevin Furlong, Rahul S. Kathayat, Mason R. Firpo, Vincent Mastrodomenico, Emily A. Bruce, Madaline M. Schmidt, Robert Jedrzejczak, Miguel Á. Muñoz-Alía, Brooke Schuster, Vishnu Nair, Jason W. Botten, Christopher B. Brooke, Susan C. Baker, Bryan C. Mounce, Nicholas S. Heaton, Bryan C. Dickinson, Andrzej Jaochimiak, Glenn Randall, Savaş Tay
Research
Repurposing potential of FDA‐approved and investigational drugs for COVID‐19 targeting SARS‐CoV‐2 spike and main protease and validation by machine learning algorithm Akalesh Kumar Verma, Rohit Aggarwal
Research
Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Zhang, ShaojunHuang, WenzeRen, LiliJu, XiaohuiGong, MingliRao, JianSun, LeiLi, PanDing, QiangWang, JianweiZhang, Qiangfeng Cliff
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
